**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 9336**

**Columns: OBSERVATIONAL STUDY**

**Clinical efficacy of tolvaptan for treatment refractory ascites in liver cirrhosis patients**

Zhang X *et al*. Tolvaptan therapy for refractory ascites

Xin Zhang, Shu-Zhen Wang,Jun-Fu Zheng, Wen-Min Zhao, Peng Li, Chun-Lei Fan, Bing Li, Pei-Ling Dong, Lei Li, Hui-Guo Ding

**Xin Zhang, Shu-Zhen Wang,Jun-Fu Zheng, Wen-Min Zhao, Peng Li, Chun-Lei Fan, Bing Li, Pei-Ling Dong, Lei Li, Hui-Guo Ding,** Department of Gastroenterology and Hepatology, Beijing You’an Hospital, Affiliated with Capital Medical University, Beijing 100069, China

**Author contributions:** Zhang X, Wang SZ equally contributed to the data collection and follow-up of patients for this manuscript; Ding HG, Zhang X, Wang SZ and Zheng JF analyzed the data; Zhang X, Wang SZ and Ding HG wrote the manuscript; Ding HG was also responsible for this project the final revised manuscript; and the other authors contributed to data acquisition and patient care.

**Supported by** the Beijing High-Level Talent Academic Leader/Personnel Training Programs awarded to Ding HG, 2011-2-19; Li B, 2013-3-072; and Li L, 2013-3-073

**Correspondence to: Hui-Guo Ding, MD, PhD,** **Director,** Department of Gastroenterology and Hepatology, Beijing You’an Hospital, Affiliated with Capital Medical University, Fengtai District, Beijing 100069, China. [dinghuiguo@medmail.com.cn](mailto:dinghuiguo@medmail.com.cn)

**Telephone:** +86-10-83997155 **Fax:** +86-10-63295525

**Received:** February 8, 2014 **Revised:** April 11, 2014

**Accepted:** May 12, 2014

**Published online:**

**Abstract**

**AIM:** To evaluate the efficacy and safety of tolvaptan for treatment refractory ascites in decompensated liver cirrhosis patients with or without further complications, such as hepatorenal syndrome and/or hepatocellular carcinoma.

**METHODS:**Thirty-nine patients (mean age 55 years, males: 32) with decompensated liver cirrhosis and refractory ascites were enrolled. All patients received a combination of tolvaptan (15 mg/d for 5–14 d) and diuretics (40–80 mg/d of furosemide and 80–160 mg/d of spironolactone). The etiology of cirrhosis included hepatitis B (69.2%), hepatitis C (7.7%) and alcohol-induced (23.1%). Changes in the urine excretion volume, abdominal circumference and edema were assessed. The serum sodium levels were also measured, and adverse events were recorded. A follow-up assessment was conducted 1 month after treatment with tolvaptan.

**RESULTS:**Tolvaptan increased the mean urine excretion volume (1969.2 ± 355.55 mL *vs* 3410.3 ± 974.1 mL, *P* < 0.001), and 89.7% of patients had improvements in their ascites, 46.2% of whom had significant improvements. The overall efficacy of tolvaptan in all patients was 89.7%; the efficacies in patients with hepatocellular carcinoma and hepatorenal syndrome were 84.2% and 77.8%, respectively. The incidence of hyponatremia was 53.8%. In patients with hyponatremia, the serum sodium levels increased after tolvaptan treatment (from 128.1 ± 4.22 mEq/L *vs* 133.1 ± 3.8 mEq/L, *P* < 0.001). Only mild drug-related adverse events, including thirst and dry mouth, were observed.

**CONCLUSION:**Tolvaptan is a promising aquaretic for the treatment of refractory ascites in patients with decompensated liver cirrhosis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Tolvaptan; Refractory ascites; Hyponatremia; Decompensated; Liver cirrhosis

**Core tip:** This study showed that tolvaptan, a new aquaretic drug, is an effective and safe potential treatment for refractory ascites in patients with decompensated liver cirrhosis, especially in patients with further complications such as hepatorenal syndrome and/or hepatocellular carcinoma. Tolvaptan significantly increased the serum sodium levels in patients with hyponatremia.

Zhang X, Wang SZ,Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment refractory ascites in liver cirrhosis patients. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Ascites is one of the most common complications of liver cirrhosis[1]. Refractory ascites occurs in 15%-20% of all ascites patients and is defined either as an unresponsiveness to restrictions on salt intake and high-dose diuretics or as a recurrence occurring rapidly within 4 wk post-therapy, according to the American Association for the Study of Liver Diseases (AASLD) guidelines[2]. Refractory ascites is associated with a poor prognosis, and it is difficult to treat due to the limited treatment options[3–6].

Tolvaptan is a new, oral, selective vasopressin V2-receptor antagonist approved for treating hypervolemic and euvolemic hyponatremia[7,8]. The blockage of V2-receptors by tolvaptan prevents the insertion of aquaporin-2 water channels into the apical cell membrane of the collecting duct, increasing free water excretion without significantly affecting urinary sodium and potassium excretion. As a result, there is reduced water retention with elevated serum sodium levels. The tolvaptan mechanism of action indicates that it is effective for treating hyponatremia and has a significant role in promoting aquaresis.

Numerous studies have reported on the efficacy and safety of tolvaptan for treating ascites and edema in patients with decompensated cirrhosis[8-11]. However, the efficacy and safety of this drug for treating refractory ascites in cirrhotic patients remains unknown. Furthermore, the use of tolvaptan in the subset of patients with complications such as hepatorenal syndrome and/or hepatocellular carcinoma has not previously been explored.

Our principal objective was to conduct an observational study to examine the efficacy and safety of tolvaptan for treating refractory ascites and edema in decompensated cirrhotic patients with or without additional complications.

**MATERIALS AND METHODS**

***Study design***

A single center, open-label, observational study was conducted in China between May 2012 and July 2013. Patients were recruited between May 2012 and March 2013.

***Inclusion criteria***

Candidates were selected for study inclusion if they met the criteria for cirrhosis and refractory ascites. A diagnostic work-up for decompensated liver cirrhosis was performed, including assessment of the clinical manifestations, physical examination and laboratory tests. The inclusion criteria were as follows: (1) history of chronic hepatitis and/or signs with various causes; (2) abnormal liver function accompanied by portal hypertension, such as ascites, encephalopathy or esophageal or gastric variceal bleeding; and (3) B-ultrasound scanning (LOGIQ9; GE Company, Fairfield, United States) and 4-phase multidetector computed tomography (CT) scan (GE HISPEED DXI; GE Company) results consistent with the signs of liver cirrhosis. Patients with hepatocellular carcinoma were diagnosed using CT or dynamic contrast-enhanced magnetic resonance imaging in accordance with the diagnostic criteria recommended in the 2010 AASLD guidelines[12].The definition for refractory ascites underwent a minor revision according to the 2012 AASLD guidelines[2]. Namely, refractory ascites was defined as if it was not satisfactorily controlled after a patient had either (1) 1 week of sodium intake restrictions (< 6 g/d), intermittent albumin infusion (10–20 g per treatment) and high doses of diuretics (more than 160 mg/d of furosemide and 200 mg/d of spironolactone); or (2) 2 wk of therapeutic paracentesis (3000–5000 mL per treatment). Hepatic encephalopathy was assessed in accordance with the guidelines developed by the American Gastroenterological Association[13]. Patients were diagnosed with hepatorenal syndrome in accordance with the International Ascites Club guidelines[14]. Patients were excluded if they had severe cardiovascular, pulmonary, cerebral or hematological complications or severe mental illness.

***Ethics***

The current study was approved by the ethics committee of Beijing You’an Hospital, Capital Medical University (protocol number 2011-015) and was performed in accordance with the ethical standards set forth in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from patients and their families before study participation.

***Therapeutic protocol***

All patients received oral tolvaptan (15 mg/d for 5–14 d) in addition to a concurrent treatment regimen of sodium intake restrictions (< 6 g/d), intermittent albumin infusion (10–20 g per treatment) and standard diuretic therapy (40–80 mg/d of furosemide and 80–160 of mg/d spironolactone). Patients with abdominal infection were given antibiotics prior to tolvaptan treatment, and patients with coexisting hepatic encephalopathy also underwent a routine treatment regimen of lactulose and neomycin. A follow-up assessment was conducted 1-month post-tolvaptan treatment for all patients.

Serum markers for hepatitis B virus and hepatitis C virus were detected using an electrochemiluminescence immunoassay in accordance with the manufacturer’s protocol (Roche E170 modular immunoassay analyzer, Roche Diagnostics, Mannheim, Germany). Liver and renal function, including the serum sodium and potassium levels, serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, creatinine and urea nitrogen, was tested with an automatic biochemical analyzer (AU5400, Olympus, Japan).

***Efficacy assessment***

For ascites, the urine volume was measured over 24 h; we also measured the abdominal circumference and edema of the lower extremities, which were assessed in the morning while the participants had an empty stomach. The overall efficacy of tolvaptan for treating ascites was assessed with a set of three evaluation indicators, which are detailed in Table 1.

***Survival***

The number of patients who survived after 1 month was recorded to examine the relationship between the short-term correction of hyponatremia and the prognostic improvement.

***Safety assessment***

Patients were monitored throughout the study period, and any occurrence of adverse events and deaths was recorded.

***Statistical analysis***

Parametric data are expressed as a mean ± standard deviation (mean ± SD) and were assessed using two-tailed *t*-tests. Levene’s test for equality of variance was conducted concurrently for all t-tests. Categorical data were compared using the Pearson’s Chi-squared (*χ*2) test. The Kaplan–Meier method was used to estimate the 1-month cumulative patient survival, and between-group differences were tested for significance using the log-rank test. All *P*-values < 0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics software (IBM, version 12.0).

**RESULTS**

***Patient characteristics***

Thirty-nine patients who met the study’s eligibility requirements were included. The demographics and other baseline characteristics of these patients are detailed in Table 2.

***Ascites and edema***

The administration of tolvaptan resulted in a significant increase in the mean urine excretion volume from 1969.2 ± 355.55 mL pre-treatment to 3410.3 ± 974.1 mL post-treatment [*t*(48) = -8.679, *P* < 0.001; *n* = 39]. Levene’s test indicated that there were unequal variances in the data sets (*F* = 27.115, *P* < 0.001); as a result, the degrees of freedom were adjusted from 76 to 48. The combination of tolvaptan with diuretics was effective in increasing the urine output in 89.7% of patients with refractory ascites (Table 3). The abdominal circumference was reduced in 82% of patients, and edema was also improved in 91.7% of patients (Table 3).

The overall efficacy of tolvaptan was 89.7% (*n* = 35) in all patients, and 46.2% (*n* = 18) of these patients had significant improvement (Table 3 and Figure 1). Subgroup analyses indicated that the overall efficacy of tolvaptan in patients with coexisting hepatocellular carcinoma was 84.2% (*n* = 19) and that the efficacy for patients with coexisting hepatorenal syndrome was 77.8% (*n* = 9; Table 3 and Figure 1). Tolvaptan was not effective for treating refractory ascites in patients with coexisting Type 1 hepatorenal syndrome.

***Hyponatremia***

The incidence of hyponatremia (defined as a serum sodium concentration < 135 mEq/L) was 53.8% (21 of 39 patients) in cirrhotic patients with refractory ascites. Tolvaptan caused a significant increase in the serum sodium concentration in patients with hyponatremia (from 128.1 ± 4.22 to 133.1 ± 3.8 mEq/L; Figure 2). There was no significant change in the serum sodium concentration for patients lacking hyponatremia after tolvaptan treatment (137.8 ± 3.02 mEq/L before treatment and 136.9 ± 3.18 mEq/L after treatment; Figure 2). There was no significant relationship between the short-term correction of hyponatremia and the 1-month patient survival rate [Figure 3; *χ*2 (2, *n* = 39) = 0.454, *P* > 0.05].

***Adverse events***

The mild adverse events of thirst and dry mouth associated with tolvaptan treatment were reported in 4 and 2 patients, respectively. No other drug-related adverse events or liver function abnormalities were observed in this study. Improvements were observed in 11 of 13 patients who had coexisting hepatic encephalopathy. In patients with hepatorenal syndrome, 5 of 7 patients with Type 2 syndrome showed improvements during treatment, while 2 patients with coexisting Type 1 syndrome experienced continuous deterioration of their renal function.

**DISCUSSION**

The current theory for the development of ascites is complex and has recently evolved to include previously proposed mechanisms[5]. However, to fully understand how tolvaptan affects refractory ascites, the pathogenesis of ascites needs to be briefly explored.

The formation of ascites involves an increase in the hepatic portal vein pressure, which may cause systemic arterial vasodilation, resulting in a decrease in the effective blood volume[15-17]. This decrease in blood volume triggers the activation of the sympathetic nervous system and renin-angiotensin system, and the resultant cascade of events causes the release of arginine vasopressin (AVP, which is alternatively termed antidiuretic hormone). AVP plays a critical role in water reabsorption in the renal collecting ducts[5,8]. However, as mentioned previously, the treatments for refractory ascites are limited. A diet of controlled salt intake, adequate diuretics treatment, large-volume paracentesis, transjugular intrahepatic portosystemic shunting and liver transplantation are the current clinical recommendations[3,18] However, targeting the AVP mechanism presents a potential novel treatment approach for refractory ascites.

Tolvaptan has been shown to improve ascites and edema in patients with decompensated liver disease, but its efficacy has not previously been explored in the subset of patients with refractory ascites. In the current study, the combination of tolvaptan with diuretics was effective in increasing urine output, decreasing abdominal circumference and reducing edema in patients with refractory ascites. Tolvaptan was effective at treating a substantial proportion of all patients, and 46.2% of the responders experienced significant improvement. Therefore, this study shows that the combination of tolvaptan with diuretics is more effective than standard options for treating refractory ascites in decompensated cirrhotic patients with or without further complications, such an hepatocellular carcinoma and/or hepatorenal syndrome.

A number of studies have demonstrated the efficacy of tolvaptan for treating hyponatremia[19-23]. In this study, tolvaptan significantly increased the serum sodium levels of patients with hyponatremia, while no significant difference was observed for patients lacking hyponatremia, supporting the efficacy of this drug in end-stage cirrhotic patients who have refractory ascites and hyponatremia. A 1-month follow-up assessment revealed that our treatment regimen corrected hyponatremia in 9 of 21 patients (42.9%). This observation is supported by reports from Berl *et al*[19]. While the relationship between the short-term correction of hyponatremia and survival was not statistically significant, this study had a small sample size. As a result, further studies are warranted to validate this finding. Further investigations are also warranted for definitively assessing the clinical use of tolvaptan for treating refractory ascites in patients with decompensated liver cirrhosis.

In January 2013, the US FDA issued a warning for tolvaptan use because of the potential risks of liver injury that were identified during clinical trial testing of the use of tolvaptan treatment for autosomal dominant polycystic kidney disease. The study found that 3 of 1445 cases treated with tolvaptan had significantly higher serum bilirubin and ALT. However, the clinical trial tolvaptan dose (120 mg/d for 3 years) was significantly higher, and the administration duration was longer than the recommended dosing strategy (15-60 mg/d for 7-30 d) for treating hyponatremia or ascites[24-26].The United States, Japan and Europe are the main regions using tolvaptan in the clinic. Currently, there are only 311 cases of self-reported adverse events, and there are no reports of liver injury. Therefore, administering a lower dose of tolvaptan over a shorter treatment regimen does not affect liver function in patients with preexisting liver disease, such as liver cirrhosis.

In summary, the results of this observational study show that tolvaptan is effective for treating refractory ascites and/or edema in decompensated cirrhotic patients and that it is therefore a promising aquaretic agent.

**ACKNOWLEDGMENTS**

The authors would like to acknowledge Health Interactions Asia Pacific Pte Ltd for language polishing and the writing assistance of the Korea Otsuka Pharmaceutical Co., Ltd. We also thank Ms. YJ Park for her support in acting as a liaison for medical writing assistance.

**COMMENTS**

***Background***

Tolvaptan, a new oral, selective vasopressin V2-receptor antagonist, is reported as an effective treatment for hyponatremia. Tolvaptan has a significant role in promoting aquaresis in patients with decompensated cirrhosis. However, the efficacy and safety of this drug for treating refractory ascites in cirrhotic patients and the effect(s) of tolvaptan use in patients with hepatorenal syndrome and/or hepatocellular carcinoma have not been previously studied.

***Research frontiers***

Numerous studies have reported on the efficacy and safety of tolvaptan for the treatment of ascites and edema and have demonstrated the efficacy of tolvaptan for treating hyponatremia in patients with decompensated cirrhosis.

***Innovations and breakthroughs***

This study shows that the combination of tolvaptan with diuretics is more effective than standard treatment approaches for refractory ascites in decompensated cirrhotic patients with or without further complications, such an hepatocellular carcinoma and/or hepatorenal syndrome.

***Applications***

Tolvaptan is a promising aquaretic agent that can be used for the treatment of refractory ascites and/or edema in decompensated cirrhotic patients.

***Terminology***

Refractory ascites is defined as 1 week of unresponsiveness to restrictions on salt intake and high-dose diuretics (more than 160 mg/d of furosemide and 200 mg/d of spironolactone) or recurrence occurring within 2 wk post-therapeutic paracentesis (removal of 3000–5000 mL of ascites per treatment) and intermittent albumin infusion.

***Peer review***

This manuscript is the first reported open study showing that a short term (4-15 d) therapy with 15 mg/d of tolvaptan for refractory ascites in decompensated cirrhotic patients, as well as in patients with hepatorenal syndrome type 2 and hepatocellular carcinoma, is effective and safe. This is an interesting study.

**REFERENCES**

1 **Gordon FD**. Ascites. *Clin Liver Dis* 2012; **16**: 285-299 [PMID: 22541699 DOI: 10.1016/j.cld.2012.03.004]

2 **Runyon BA**; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology* 2013; **57**: 1651-1653 [PMID: 23463403 DOI: 10.1002/hep.26359]

3 **Bhogal H**, Sanyal AJ. Treatment of refractory ascites. *Clin Liver Dis* 2013; **2**: 140–142 doi: 10.1002/cld.211

4 **Singhal S**, Baikati KK, Jabbour II, Anand S. Management of refractory ascites. *Am J Ther* 2012; **19**: 121-132 [PMID: 21192246 DOI: 10.1097/MJT.0b013e3181ff7a8b]

5 **Moore CM**, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. *World J Hepatol* 2013; **5**: 251-263 [PMID: 23717736 DOI: 10.4254/wjh.v5.i5.251]

6 **Yu C**, Sharma N, Saab S. Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis. *Exp Clin Transplant* 2013; **11**: 3-11 [PMID: 23387536]

7 **Josiassen RC**, Curtis J, Filmyer DM, Audino B, Skuban N, Shaughnessy RA. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders. *Expert Opin Pharmacother* 2010; **11**: 637-648 [PMID: 20163274 DOI: 10.1517/14656561003610656]

8 **Gaglio P**, Marfo K, Chiodo J. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan. *Dig Dis Sci* 2012; **57**: 2774-2785 [PMID: 22732834 DOI: 10.1007/s10620-012-2276-3]

9 **Sakaida I**, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. *J Int Med Res* 2013; **41**: 835-847 [PMID: 23685892 DOI: 10.1177/0300060513480089]

10 **Okita K**, Kawazoe S, Hasebe C, Kajimura K, Kaneko A, Okada M, Sakaida I. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial. *Hepatol Res* 2014; **44**: 83-91 [PMID: 23530991 DOI: 10.1111/hepr.12099]

11 **Sakaida I**, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. *Hepatol Res* 2014; **44**: 73-82 [PMID: 23551935 DOI: 10.1111/hepr.12098]

12 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

13 **Blei AT**, Córdoba J. Hepatic Encephalopathy. *Am J Gastroenterol* 2001; **96**: 1968-1976 [PMID: 11467622 DOI: 10.1111/j.1572-0241.2001.03964.x]

14 **Salerno F**, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. *Gut* 2007; **56**: 1310-1318 [PMID: 17389705]

15 **Leiva JG**, Salgado JM, Estradas J, Torre A, Uribe M. Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents. *Ann Hepatol* 2007; **6**: 214-221 [PMID: 18007550]

16 **Schrier RW**. Decreased effective blood volume in edematous disorders: what does this mean? *J Am Soc Nephrol* 2007; **18**: 2028-2031 [PMID: 17568020 DOI: 10.1681/ASN.2006111302]

17 **Hou W**, Sanyal AJ. Ascites: diagnosis and management. *Med Clin North Am* 2009; **93**: 801-17, vii [PMID: 19577115 DOI: 10.1016/j.mcna.2009.03.007]

18 **Chen RP**, Zhu Ge XJ, Huang ZM, Ye XH, Hu CY, Lu GR, Lu de Y, Phemba IL. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. *J Clin Gastroenterol* 2014; **48**: 290-299 [PMID: 24030734 DOI: 10.1097/MCG.0b013e3182a115e9]

19 **Berl T**, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. *J Am Soc Nephrol* 2010; **21**: 705-712 [PMID: 20185637 DOI: 10.1681/ASN.2009080857]

20 **Cárdenas A**, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. *J Hepatol* 2012; **56**: 571-578 [PMID: 22027579 DOI: 10.1016/j.jhep.2011.08.020]

21 **Schrier RW**, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006; **355**: 2099-2112 [PMID: 17105757 DOI: 10.1056/NEJMoa065181]

22 **Miyazaki T**, Fujiki H, Yamamura Y. Tolvaptan, an orally active non-peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury. *Hepatol Res* 2013; **43**: 1224-1230 [PMID: 23413814 DOI: 10.1111/hepr.12073]

23 **Habib S**, Boyer TD. Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia. *Therap Adv Gastroenterol* 2012; **5**: 189-197 [PMID: 22570679 DOI: 10.1177/1756283X12437357]

24 **Torres VE**, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012; **367**: 2407-2418 [PMID: 23121377 DOI: 10.1056/NEJMoa1205511]

25 **Okita K**, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, Sata M, Yoshihara H, Ono N, Murawaki Y. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. *J Gastroenterol* 2010; **45**: 979-987 [PMID: 20387081 DOI: 10.1007/s00535-010-0240-6]

26 **Sakaida I**, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. *Hepatol Res* 2013; In press [PMID: 23711300 DOI: 10.1111/hepr.12171]

**P-Reviewers:** Guglielmi FW, Satapathy SK, Trapero-Marugan M, Wong GLH **S-Editor:** Gou SX  **L-Editor: E-Editor:**

****

**Figure 1 Overall efficacy of 15 mg/d tolvaptan.** Overall efficacy of 15 mg/d tolvaptan for 5–14 d in all patients as well as in subgroups of patients with coexisting hepatocellular carcinoma (HCC) and hepatorenal syndrome (HRS) post-tolvaptan treatment.

****

**Figure 2 The effects of tolvaptan on serum sodium (mean ± SE) in patients with and without hyponatremia (*n* = 21 and *n* = 18, respectively).** Tolvaptan (15 mg/d, 5–14 d) treatment (black column) significantly increased serum sodium concentration [*t*(40) = -4.029, b*P* < 0.01 *vs* before treatment group] in patients with hyponatremia, but not in patients without hyponatremia [*t*(32) = 1.545, *P* > 0.05 (NS)].



**Figure 3 Tolvaptan does not affective liver function elements.** A: Tolvaptan (15 mg/d for 5–14 d) does not affective liver function elements [model for end-stage liver disease (MELD) score, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] in patients with preexisting liver cirrhosis (*P* > 0.05); B:Kaplan–Meier analysis of the 1-mo survival of patients without hyponatremia as well as with and without short-term correction of hyponatremia did not show any significant difference between patient groups.

**Table 1 Definitions for grades, which represent the measures of improvement for the urine excretion volume, ascites and edema**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Measure of improvement** | | |
|  | **Significant improvement** | **Improvement** | **No improvement** |
|  | **Grade** | | |
|  | **A** | **B** | **C** |
| Volume of urine excretion | Increased by >1000 mL/24 h | Increased by 500–1000 mL/24 h | Increased by < 500 mL/24 h |
| Abdominal circumference | Decreased by > 2 cm | Decreased by 0–2 cm | No change |
| Edema  (lower extremities) | A lack of visible pitting | Presence of visible pitting | Distinctly visible pitting |

**Table 2** **Baseline characteristics of the cirrhotic patients with refractory ascites who were included in the study*****n* (%)**

|  |  |  |
| --- | --- | --- |
| **Baseline characteristics** | | **Value** |
| Total number of patients | | 39 |
| Age (yr) † | | 55.0 ± 12.4 |
| Sex | Male | 32 (82.0) |
|  | Female | 7 (17.9) |
| Underlying liver disease | Cirrhosis | 20 (51.3) |
| Cirrhosis with hepatocellular carcinoma | 19 (48.7) |
| Liver disease pathogenesis | HBV infection | 27 (69.2) |
| HCV infection | 3 (7.69) |
| Alcoholic cirrhosis | 9 (23.1) |
| Coexisting hepatorenal syndrome | Type 1 | 2 (5.13) |
|  | Type 2 | 7 (17.9) |
| Coexisting hepatic encephalopathy | | 13 (33.3) |
| Child–Pugh score | Class C | 39 (11.8 ± 1.5) |
| MELD score |  | 39 (37.5 ± 5.6) |
| Coexisting diabetes | | 9 (23.1) |
| Hyponatremia | Yes | 21 (53.8) |
|  | No | 18 (46.2) |

Data are expressed as absolute numbers (percentage) or mean ± SD. HBV: Hepatitis B virus; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease.

**Table 3 Summary of the improvement in the urine excretion, ascites and edema after tolvaptan treatment, according to grading criteria, and in the overall improvement *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | ***n*** | **Significant improvement** | **Improvement** | **No improvement** |
| Urine excretion | 39 | 26 (66.7) | 9 (23.1) | 4 (10.3) |
| Abdominal circumference | 39 | 19 (48.7) | 13 (33.3) | 7 (17.9) |
| Edema  (lower extremities) | 24 | 17 (70.8) | 5 (20.8) | 2 (8.3) |
| Overall improvement for all patients1 | 39 | 18 (46.2) | 17 (43.6) | 4 (10.2) |
| Overall improvement in patients with coexisting hepatocellular carcinoma1 | 19 | 9 (47.4) | 7 (36.8) | 3 (15.8) |
| Overall improvement in patients with coexisting hepatorenal syndrome (Type 1)1 | 2 | 0 (0) | 0 (0) | 2 (100.0) |
| Overall improvement in patients with coexisting hepatorenal syndrome (Type 2)1 | 7 | 2 (28.6) | 5 (71.4) | 0 (0) |

1Overall improvement definitions: Significant improvement = grade of A for urine excretion, ascites and edema; Improvement = grade of B for urine excretion and a grade of improvement for ascites or edema; No improvement = grade of C for urine excretion.